Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07018206 · ClinicalTrials.gov registry record · Phase 4
Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis
A Phase 4 study, sponsored by Care Arthritis.
- Not yet
- Registry status
- Phase 4
- Development phase
- 200
- Enrollment target
NCT07018206: Clinical Trial Phase 4 study, sponsored by Care Arthritis.
NCT07018206 is a Phase 4 study that has not yet begun recruiting, run by Care Arthritis. The registered enrollment target is 200 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07018206, a Phase 4 study, has not yet begun recruiting, sponsored by Care Arthritis.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 200 participants
- Enrollment target
Study Summary
This is a Phase IV, open-label, multicenter study evaluating the impact of upadacitinib on the frequency of acute anterior uveitis (AAU) in adults with axial spondyloarthritis (axSpA) and a documented history of AAU in the prior 52 weeks. Approximately 200 participants will be enrolled across North America and Europe, including both biologic DMARD-inadequate responders (bDMARD-IR) and bDMARD-naïve patients. The primary objective is to assess the change in exposure-adjusted AAU event rate during 52 weeks of treatment with upadacitinib 15 mg once daily. Secondary objectives include evaluating the effect of upadacitinib on disease activity, pain, physical function, quality of life, and sleep. Safety and tolerability will also be assessed throughout the study.
Primary Outcome
To evaluate the impact of upadacitinib on the frequency of recurrent acute anterior uveitis (AAU) over 52 weeks in subjects with active axSpA and a prior AAU event in the 52 weeks prior to baseline, who are switching from bDMARD (North America and Europe), or who are NSAID-IR and bDMARD naïve (Europe), in real world practice.
Interventions
- DRUG Upadacitinib 15 MG [Rinvoq]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2026-05 |
| Est. Completion | 2027-05 |
| Phase | Phase 4 |
What is known before NCT07018206 opens enrollment
NCT07018206 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which Upadacitinib 15 MG [Rinvoq] is the first listed.
NCT07018206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07018206 about?
NCT07018206 is a clinical study titled "Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis". This is a Phase IV, open-label, multicenter study evaluating the impact of upadacitinib on the frequency of acute anterior uveitis (AAU) in adults with axial spondyloarthritis (axSpA) and a documented history of AAU in the prior 52 weeks. Approximately 200 participants will be enrolled across North ...
What is the current status of trial NCT07018206?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 200 participants. The study started on 2026-05. Estimated completion is 2027-05.
What interventions are being tested in trial NCT07018206?
The interventions under investigation include: Upadacitinib 15 MG [Rinvoq] (DRUG).
Who is sponsoring clinical trial NCT07018206?
This trial is sponsored by Care Arthritis, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07018206's enrollment target sits among peer trials
200 407th of 2000 higher than 1,556 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia